![share_log](https://usnewsfile.moomoo.com/20230625000012291e57d0213b0.jpg?imageMogr2/thumbnail/76x76!/ignore-error/1/format/webp)
牛牛AI助理已提取核心訊息
60 Degrees Pharmaceuticals, Inc. reported its financial performance for the quarter ended June 30, 2024, with a significant increase in product revenues, primarily driven by domestic sales of its malaria prevention drug, Arakoda. Product revenues reached $124,972, a 109.92% increase from the previous year's quarter, while service revenues remained at zero. The cost of revenues decreased by 51.32% to $89,564, resulting in a gross profit of $35,408, marking a substantial improvement from the prior year's gross loss. Research revenues were minimal at $728. Operating expenses saw a sharp rise, with research and development costs at $3,095,326, mainly due to expenses related to the planned babesiosis trial for tafenoquine and a significant expense recognized upon delivery of a report from Kentucky Technology, Inc. General and administrative expenses also increased...Show More
60 Degrees Pharmaceuticals, Inc. reported its financial performance for the quarter ended June 30, 2024, with a significant increase in product revenues, primarily driven by domestic sales of its malaria prevention drug, Arakoda. Product revenues reached $124,972, a 109.92% increase from the previous year's quarter, while service revenues remained at zero. The cost of revenues decreased by 51.32% to $89,564, resulting in a gross profit of $35,408, marking a substantial improvement from the prior year's gross loss. Research revenues were minimal at $728. Operating expenses saw a sharp rise, with research and development costs at $3,095,326, mainly due to expenses related to the planned babesiosis trial for tafenoquine and a significant expense recognized upon delivery of a report from Kentucky Technology, Inc. General and administrative expenses also increased to $1,129,560, reflecting higher compensation and related expenses. The company reported a net loss of $4,172,755, attributed to 60 Degrees Pharmaceuticals, Inc., which included a minor loss from the change in fair value of derivative liabilities and a small amount of other net income. The company's cash used in operating activities was $2,328,650 for the six months ended June 30, 2024. The report also highlighted a reverse stock split effective August 12, 2024, and the sale of 677,819 shares under an At-the-Market Issuance Sales Agreement, generating proceeds of $1,994,583. The company's financial statements have been prepared on a going concern basis, despite not having demonstrated the ability to generate enough revenues to cover operating expenses to date.
60度藥業公司報告截至2024年6月30日的財務表現,產品收入顯著增加,主要是由國內瘧疾預防藥物阿拉科達的銷售推動。產品收入達到124,972美元,比上年同期增長109.92%,而服務收入仍爲零。營業成本下降了51.32%,爲89,564美元,實現毛利潤35,408美元,較上一年的毛損有較大改善。研究收入微不足道,僅爲728美元。營業費用大幅增加,研發成本爲3,095,326美元,主要是由於與沙非諾喹計劃的微小體試驗、以及肯塔基技術公司報告交付後確認的巨大費用相關。總行政費用也增加到1,129,560美元,反映了更高的薪酬和相關費用。公司報告淨損失爲4,172,755美元,歸屬於60度藥業公司...展開全部
60度藥業公司報告截至2024年6月30日的財務表現,產品收入顯著增加,主要是由國內瘧疾預防藥物阿拉科達的銷售推動。產品收入達到124,972美元,比上年同期增長109.92%,而服務收入仍爲零。營業成本下降了51.32%,爲89,564美元,實現毛利潤35,408美元,較上一年的毛損有較大改善。研究收入微不足道,僅爲728美元。營業費用大幅增加,研發成本爲3,095,326美元,主要是由於與沙非諾喹計劃的微小體試驗、以及肯塔基技術公司報告交付後確認的巨大費用相關。總行政費用也增加到1,129,560美元,反映了更高的薪酬和相關費用。公司報告淨損失爲4,172,755美元,歸屬於60度藥業公司,其中包括公允價值變動損失的微小損失和少量的其他淨收入。公司在2024年6月30日結束的六個月中,經營活動使用的現金爲2,328,650美元。報告還強調了2024年8月12日生效的股票反向分割,以及在市場發行銷售協議下售出的677,819股股份,收入1,994,583美元。儘管無法證明具備足夠收入以支付日常經營費用,但公司的財務報表是以繼續經營爲前提製定的。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了